Company Encyclopedia
View More
name
Personalis
PSNL.US
Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for the detection of MRD; and NeXT Dx, a tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient.
770.89 B
PSNL.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
Life Sciences Tools and ServicesIndustry
Industry Ranking49/60
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-43.69%E
    • Profit Margin-106.92%E
    • Gross Margin13.20%D
  • Growth ScoreD
    • Revenue YoY-21.02%E
    • Net Profit YoY19.20%B
    • Total Assets YoY1.23%C
    • Net Assets YoY2.79%C
  • Cash ScoreD
    • Cash Flow Margin-93.53%D
    • OCF YoY-21.02%E
  • Operating ScoreD
    • Turnover0.29D
  • Debt ScoreB
    • Gearing Ratio29.41%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Personalis, Inc. Announces $100 Million Stock Offering

    On November 28, 2025, Personalis, Inc. announced a $100 million common stock offering. Key Highlights: Filed a prospectus supplement for $100M stock sale.Shares offered under an amended sales agreement.Cooley LLP provided legal opinion on the offering.Original SEC Filing: Personalis, Inc. [ PSNL ] - 8-K - Nov. 28, 2025DisclaimerThis is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

    TradingView·
    US
    PSNL
    +3.05%
    TradingView·
    US
    PSNL
    +3.05%

    COO Tachibana Sells 103,668 ($1.1M) Of Personalis Inc [PSNL]

    Tachibana Aaron, COO of Personalis Inc [PSNL], sold 103,668 shares worth $1.1M on November 25, 2025, as disclosed in a Form 4 filed with the SEC. The sale was executed under a prearranged trading plan (10b5-1).

    Reuters·
    US
    PSNL
    +3.05%
    Reuters·
    US
    PSNL
    +3.05%

    Personalis CFO and COO Aaron Tachibana Reports Disposal of Common Shares

    Aaron Tachibana, CFO and COO of Personalis Inc., reported the disposal of common shares of the company. The details were published via EDGAR by the U.S. SEC. This information is for informational purposes and not financial advice.

    Reuters·
    US
    PSNL
    +3.05%
    Reuters·
    US
    PSNL
    +3.05%

    COO Tachibana Files To Sell 103,668 Of Personalis Inc [PSNL]

    Tachibana Aaron, COO of Personalis Inc, filed a Form 144 with the SEC to sell 103,668 shares of restricted stock on November 25, 2025. The sale is executed under a prearranged trading plan (10b5-1) through Morgan Stanley Smith Barney LLC. Filing Form 144 is a prerequisite for selling restricted securities, allowing the sale within 90 days of filing.

    Reuters·
    US
    PSNL
    +3.05%
    Reuters·
    US
    PSNL
    +3.05%

    The Nasdaq Biotechnology Index closed up nearly 1.4%, closely mirroring the performance of the Dow Jones Industrial Average. Among the constituent stocks, Esperion rose 16.09%, ARS Pharmaceuticals rose 15.50%, Anavex Life Sciences rose 12.34%, Personalis rose 12.31%, Autolus Therapeutics rose 12.10%, and Aura Biosciences rose 11.09%. AC Immune fell 5.84%, LENZ Therapeutics fell 6.51%, and Cullinan Oncology LLC fell 8.82%

    Wallstreetcn·
    US
    PSNL
    +3.05%
    US
    SPRY
    +4.40%
    US
    AURA
    +2.38%
    Wallstreetcn·
    US
    PSNL
    +3.05%
    US
    SPRY
    +4.40%
    US
    AURA
    +2.38%
    © 2025 Longbridge｜Disclaimer